A detailed history of Level Four Advisory Services, LLC transactions in Genmab A/S stock. As of the latest transaction made, Level Four Advisory Services, LLC holds 16,620 shares of GMAB stock, worth $336,555. This represents 0.02% of its overall portfolio holdings.

Number of Shares
16,620
Previous 42,288 60.7%
Holding current value
$336,555
Previous $1.03 Million 66.41%
% of portfolio
0.02%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

SELL
$20.02 - $24.15 $513,873 - $619,882
-25,668 Reduced 60.7%
16,620 $346,000
Q3 2024

Nov 14, 2024

BUY
$23.84 - $28.48 $717,011 - $856,564
30,076 Added 246.28%
42,288 $1.03 Million
Q2 2024

Aug 09, 2024

BUY
$25.13 - $30.27 $132,460 - $159,553
5,271 Added 75.94%
12,212 $306,000
Q4 2023

Feb 08, 2024

SELL
$27.94 - $35.44 $62,613 - $79,421
-2,241 Reduced 24.41%
6,941 $221,000
Q3 2023

Nov 13, 2023

SELL
$35.27 - $42.24 $17,740 - $21,246
-503 Reduced 5.19%
9,182 $323,000
Q2 2023

Jul 10, 2023

BUY
$37.4 - $42.94 $39,382 - $45,215
1,053 Added 12.2%
9,685 $368,000
Q1 2023

Jun 05, 2023

BUY
$34.88 - $43.22 $71,259 - $88,298
2,043 Added 31.01%
8,632 $325,000
Q4 2022

Feb 13, 2023

SELL
$33.8 - $47.06 $99,811 - $138,968
-2,953 Reduced 30.95%
6,589 $279,000
Q3 2022

Nov 07, 2022

SELL
$31.52 - $373.61 $882 - $10,461
-28 Reduced 0.29%
9,542 $307,000
Q2 2022

Aug 08, 2022

SELL
$26.83 - $38.57 $39,332 - $56,543
-1,466 Reduced 13.28%
9,570 $311,000
Q1 2022

May 10, 2022

BUY
$30.95 - $39.68 $341,564 - $437,908
11,036 New
11,036 $399,000
Q4 2021

Feb 11, 2022

SELL
$35.87 - $47.12 $308,302 - $404,996
-8,595 Closed
0 $0
Q3 2021

Oct 12, 2021

BUY
$41.55 - $48.72 $357,122 - $418,748
8,595 New
8,595 $376,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.3B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Level Four Advisory Services, LLC Portfolio

Follow Level Four Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Level Four Advisory Services, LLC with notifications on news.